

# Competitor Analysis: Targeted Therapy of Diabetes

<https://marketpublishers.com/r/C2D9A236FDCEN.html>

Date: April 2011

Pages: 114

Price: US\$ 1,735.00 (Single User License)

ID: C2D9A236FDCEN

## Abstracts

### Product description

The present Competitive Intelligence Report about Targeted Therapy of Diabetes provides a competitor evaluation in the field of novel molecules being developed for treatment of type 1 and 2 diabetes as of April 2011. Major pharmacologic approaches include insulin, PPAR agonists, DPP-IV inhibitors, GLP-1 analogs and SGLT inhibitors. Furthermore, emerging approaches for diabetes therapy are reported including glucokinase activators and 11beta-HSD1 inhibitors. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of novel molecules for treatment of type 1 and 2 diabetes. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

## **Insulin**

Rec Human Insulin for Injection (2nd Generation)

Biosimilar Rec Human Insulin for Injection (2nd Generation) in

Regulated Markets

Rhu Insulin (2nd Generation) in Off-Patent Countries: China

Rhu Insulin (2nd Generation) in Off-Patent Countries: Russia

Rhu Insulin (2nd Generation) in Off-Patent Countries: India

Rhu Insulin (2nd Generation) in Off-Patent Countries: Others

Modern Insulin Analogs (3rd Generation) for Injection

Modern Insulin Analogs (3rd Generation) in Less-Regulated Markets

Tailored and Novel Insulin Analogs (4th Generation) for

Injection

Human Insulin with Drug Delivery for Injection

Other Long-Acting Insulin for Injection

Transgenic Human Insulin for Injection

Insulin/GLP-1 Combination Products

Inhaled Insulin

Oral Insulin

Transdermal Insulin

Others

## **PPAR Agonists**

PPAR alpha Agonists

PPAR gamma Agonists / Insulin Sensitizer

PPAR alpha and gamma Agonists

PPAR delta Agonists

PPAR delta and gamma Agonists

PPAR alpha and delta Agonists

PPAR pan Agonists (alpha, gamma and delta)

Unspecified PPAR Agonists

## **Dipeptidyl peptidase-IV (DPP-IV) Inhibitors**

GLP-1 Receptor Agonists

GLP-1 Analogs with Daily SC Injections

GLP-1 Analogs with Once Weekly SC Injections

GLP-1 Analogs with Bi-Weekly or Monthly SC Injections

Other GLP-1 Analogs for SC Injections

GLP-1 Analogs in Drug Delivery Formulations/Devices for

Parenteral Administration

GLP-1 Analogs in Drug Delivery Formulations for Oral

Administration

Oral Small Molecule GLP-1 Receptor Agonists

Dual Target GLP-1 Receptor Agonists / Combination Products

GLP-1 Analogs in Other, Non-Diabetes Indications

## **Sodium-Dependent Glucose Co-Transporter 2 (SGLT-2) Inhibitors**

## **11beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors**

## **Glucokinase Activators (GKA)**

## **Other Emerging Diabetes Drugs**

Adenosine Monophosphate Activated Protein Kinase (AMPK) Agonists

Sirtuin (SIRT) Activators

Protein tyrosine Phosphatase-1B (PTP-1B) Inhibitors

Glucagon Receptor (GCGR) Antagonists

Glucocorticoid Receptor (GCGR) Antagonists

Novel Insulin Sensitizers

G-Protein Coupled Receptor 119 (GPR119) Agonists

Other Drugs Augmenting GLP-1 Secretion: GPR40, GPR120 & TGR5 Agonists

Other Glucometabolic Approaches

Acyl-CoA:Diacylglycerol Acyltransferase1 (DGAT1) Inhibitors

Other Metabolic Approaches

FGF-21-Receptor Agonists

Anti-Inflammatory Approaches

Induction of Immune Tolerance

Pancreatic Beta Cell Protection & Regeneration

Pancreatic Islet Cell Transplantation

Various Antidiabetic Approaches

### **About Competitor Analysis Series:**

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

## I would like to order

Product name: Competitor Analysis: Targeted Therapy of Diabetes

Product link: <https://marketpublishers.com/r/C2D9A236FDCEN.html>

Price: US\$ 1,735.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C2D9A236FDCEN.html>